| Journal of Hematology & Oncology | |
| Immunoglobulin E induces VEGF production in mast cells and potentiates their pro-tumorigenic actions through a Fyn kinase-dependent mechanism | |
| Claudia González-Espinosa1  Mónica Lamas1  Diana González2  Alfredo Ibarra-Sánchez1  Guillermina Yanek Jiménez-Andrade1  | |
| [1] Departamento de Farmacobiología, Cinvestav, IPN, Sede Sur, Calzada de los Tenorios 235, Col. Granjas Coapa, Tlalpan CP 14330, Mexico City, Mexico;Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143-0519, USA | |
| 关键词: Inflammation; Angiogenesis; Melanoma; Fyn tyrosine kinase; VEGF; Mast cells; Immunoglobulin E; | |
| Others : 803392 DOI : 10.1186/1756-8722-6-56 |
|
| received in 2013-05-15, accepted in 2013-07-18, 发布年份 2013 | |
PDF
|
|
【 摘 要 】
Background
High concentrations of plasmatic IgE have been related to distinct systemic inflammatory conditions that frequently predispose individuals to hypersensitivity reactions. Although effects of IgE have been suggested to relay on the low-intensity activation of distinct effector elements of the immune system, such as mast cells (MC), experimental evidence on the role of IgE-induced production of inflammatory mediators on specific pathologies is scarce. MC are an important component in tumor microenvironment where they seem to secrete a number of immunomodulatory and angiogenic mediators, such as the Vascular Endothelial Growth Factor (VEGF) by not well-described mechanisms. In this work, we investigated the effect of monomeric IgE (in the absence of antigen) on the production of VEGF in MC, analyzed if monomeric IgE could exacerbate the pro-tumorigenic properties of that cell type and characterized some of the molecular mechanisms behind the effects of IgE on VEGF production and tumor growth.
Methods
For in vitro studies, murine bone marrow-derived mast cells (BMMCs) were used. Pharmacological inhibitors and phosphorylation of key elements controlling VEGF secretion and protein translation were used to characterize the mechanism of VEGF production triggered by IgE.
In vivo, the effect of a single i.v. administration of monomeric IgE on B16 melanoma tumor weight, intratumoral blood vessel formation and tumor-associated MC was assessed in four groups of mice: MC-proficient (WT), MC-deficient (Wsh), Wsh reconstituted with MC derived from WT mice (Wsh Rec WT) and Wsh reconstituted with MC derived from Fyn −/− mice (Wsh Rec Fyn −/−).
Results
Monomeric IgE induced VEGF secretion through a Fyn kinase-dependent mechanism and modulated de novo protein synthesis modifying the activity of the translational regulator 4E-BP1 in BMMCs. In vivo, monomeric IgE increased melanoma tumor growth, peritumoral MC and blood vessel numbers in WT but not in Wsh mice. The positive effects of IgE on melanoma tumor growth were reproduced after reconstitution of Wsh mice with WT but not with Fyn −/− BMMCs.
Conclusion
Our data suggest that monomeric IgE, in the absence of antigen, induces VEGF production in MC and in vivo contributes to melanoma tumor growth through a Fyn kinase-dependent mechanism.
【 授权许可】
2013 Jiménez-Andrade et al.; licensee BioMed Central Ltd.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 20140708040931107.pdf | 2502KB | ||
| Figure 8. | 80KB | Image | |
| Figure 7. | 52KB | Image | |
| Figure 6. | 58KB | Image | |
| Figure 5. | 96KB | Image | |
| Figure 4. | 51KB | Image | |
| Figure 3. | 43KB | Image | |
| Figure 2. | 49KB | Image | |
| Figure 1. | 142KB | Image |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
Figure 7.
Figure 8.
【 参考文献 】
- [1]Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, et al.: A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001, 56(9):813-824.
- [2]Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454(7203):436-444.
- [3]Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357(9255):539-545.
- [4]Kalesnikoff J, Galli SJ: New developments in mast cell biology. Nat Immunol 2008, 9(11):1215-1223.
- [5]Dyduch G, Kaczmarczyk K, Okon K: Mast cells and cancer: enemies or allies? Pol J Pathol 2012, 63(1):1-7.
- [6]Ribatti D, Crivellato E: Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta 1822, 1:2-8.
- [7]Gilfillan AM, Tkaczyk C: Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006, 6(3):218-230.
- [8]Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation. Nature 2008, 454(7203):445-454.
- [9]Xiao W, Nishimoto H, Hong H, Kitaura J, Nunomura S, Maeda-Yamamoto M, Kawakami Y, Lowell CA, Ra C, Kawakami T: Positive and negative regulation of mast cell activation by Lyn via the FcepsilonRI. J Immunol 2005, 175(10):6885-6892.
- [10]Gomez G, Gonzalez-Espinosa C, Odom S, Baez G, Cid ME, Ryan JJ, Rivera J: Impaired FcepsilonRI-dependent gene expression and defective eicosanoid and cytokine production as a consequence of Fyn deficiency in mast cells. J Immunol 2005, 175(11):7602-7610.
- [11]Kashiwakura J, Okayama Y, Furue M, Kabashima K, Shimada S, Ra C, Siraganian RP, Kawakami Y, Kawakami T: Most Highly Cytokinergic IgEs Have Poly reactivity to Auto antigens. Allergy Asthma Immunol Res 2012, 4(6):332-340.
- [12]Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I: Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ Res 2003, 92(5):485-492.
- [13]Norrby K: Mast cells and angiogenesis. APMIS 2002, 110(5):355-371.
- [14]Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P: Tumor vascularity and Tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003, 33(5):420-425.
- [15]Toth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N: Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol 2000, 31(8):955-960.
- [16]Garcia-Roman J, Ibarra-Sanchez A, Lamas M, Gonzalez Espinosa C: VEGF secretion during hypoxia depends on free radicals-induced Fyn kinase activity in mast cells. Biochem Biophys Res Commun 2010, 401(2):262-267.
- [17]Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, Galli SJ: Mast cells can secrete vascular permeability factor/ vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent up regulation of fc epsilon receptor I expression. J Exp Med 1998, 188(6):1135-1145.
- [18]Nebenfuhr A, Ritzenthaler C, Robinson DG: Brefeldin A: deciphering an enigmatic inhibitor of secretion. Plant Physiol 2002, 130(3):1102-1108.
- [19]Humeau Y, Doussau F, Grant NJ, Poulain B: How Botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82(5):427-446.
- [20]Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E: Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 1998, 18(6):3112-3119.
- [21]Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J: RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 2007, 282(19):14056-14064.
- [22]Pyronnet S, Dostie J, Sonenberg N: Suppression of cap-dependent translation in mitosis. Genes Dev 2001, 15(16):2083-2093.
- [23]Starkey JR, Crowle PK, Taubenberger S: Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988, 42(1):48-52.
- [24]Jeong HJ, Oh HA, Nam SY, Han NR, Kim YS, Kim JH, Lee SJ, Kim MH, Moon PD, Kim HM: The critical role of mast cell-derived hypoxia-inducible factor-1alpha in human and mice melanoma growth. Int J Cancer 2013, 132(11):2492-2501.
- [25]Wen R, Jou ST, Chen Y, Hoffmeyer A, Wang D: Phospholipase C gamma 2 is essential for specific functions of Fc epsilon R and Fc gamma R. J Immunol 2002, 169(12):6743-6752.
- [26]Nagai H, Sakurai T, Inagaki N, Mori H: An immuno pharmacological study of the biphasic allergic skin reaction in mice. Biol Pharm Bull 1995, 18(2):239-245.
- [27]Chen Y, Pappu BP, Zeng H, Xue L, Morris SW, Lin X, Wen R, Wang D: B cell lymphoma 10 is essential for FcepsilonR-mediated degranulation and IL-6 production in mast cells. J Immunol 2007, 178(1):49-57.
- [28]Merrill RM, Isakson RT, Beck RE: The association between allergies and cancer: what is currently known? Ann Allergy Asthma Immunol 2007, 99(2):102-116. quiz 117–109, 150
- [29]Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, Krystal G: Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 2001, 14(6):801-811.
- [30]Kitaura J, Xiao W, Maeda-Yamamoto M, Kawakami Y, Lowell CA, Kawakami T: Early divergence of Fc epsilon receptor I signals for receptor up-regulation and internalization from degranulation, cytokine production, and survival. J Immunol 2004, 173(7):4317-4323.
- [31]Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, Mocsai A, Kawakami Y, Liu FT, Lowell CA, Barisas BG, et al.: Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA 2003, 100(22):12911-12916.
- [32]Cheng LE, Hartmann K, Roers A, Krummel MF, Locksley RM: Perivascular mast cells dynamically probe cutaneous blood vessels to capture immunoglobulin E. Immunity 2013, 38(1):166-175.
- [33]Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL: Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997, 99(11):2691-2700.
- [34]Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH: Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol 2012, 189(2):511-515.
- [35]Parravicini V, Gadina M, Kovarova M, Odom S, Gonzalez-Espinosa C, Furumoto Y, Saitoh S, Samelson LE, O’Shea JJ, Rivera J: Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol 2002, 3(8):741-748.
- [36]Kohno M, Yamasaki S, Tybulewicz VL, Saito T: Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 2005, 105(5):2059-2065.
- [37]Kitaura J, Eto K, Kinoshita T, Kawakami Y, Leitges M, Lowell CA, Kawakami T: Regulation of highly cytokinergic IgE-induced mast cell adhesion by Src, Syk, Tec, and protein kinase C family kinases. J Immunol 2005, 174(8):4495-4504.
- [38]Nagy E, Berczi I, Sehon AH: Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother 1991, 34(1):63-69.
- [39]Kershaw MH, Darcy PK, Trapani JA, MacGregor D, Smyth MJ: Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 1998, 10(3):133-142.
- [40]Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, et al.: Allergo Oncology: the role of IgE-mediated allergy in cancer. Allergy 2008, 63(10):1255-1266.
- [41]Medina-Tamayo J, Ibarra-Sanchez A, Padilla-Trejo A, Gonzalez-Espinosa C: IgE-dependent sensitization increases responsiveness to LPS but does not modify development of endotoxin tolerance in mast cells. Inflamm Res 2011, 60(1):19-27.
- [42]Davison S, Galligan D, Eckert TE, Ziegler AF, Eckroade RJ: Economic analysis of an outbreak of avian influenza, 1997–1998. J Am Vet Med Assoc 1999, 214(8):1164-1167.
- [43]Gonzalez-Espinosa C, Odom S, Olivera A, Hobson JP, Martinez ME, Oliveira-Dos-Santos A, Barra L, Spiegel S, Penninger JM, Rivera J: Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. J Exp Med 2003, 197(11):1453-1465.
- [44]Matsuura T, Takahashi K, Nakayama K, Kobayashi T, Choi-Miura NH, Tomita M, Kanayama N: Increased expression of vascular endothelial growth factor in placentas of p57(Kip2) null embryos. FEBS Lett 2002, 532(3):283-288.
- [45]Manetz TS, Gonzalez-Espinosa C, Arudchandran R, Xirasagar S, Tybulewicz V, Rivera J: Vav1 regulates Phospholipase cgamma activation and calcium responses in mast cells. Mol Cell Biol 2001, 21(11):3763-3774.
- [46]Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, Frick J, Galle PR, Autenrieth I, Neurath MF: Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003, 112(5):693-706.
- [47]Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ: Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005, 167(3):835-848.
- [48]Yao J, Maslov KI, Zhang Y, Xia Y, Wang LV: Label-free oxygen-metabolic photo acoustic microscopy in vivo. J Biomed Opt 2011, 16(7):076003.
- [49]Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N: Complete inhibition of Rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000, 60(22):6253-6258.
- [50]Biggs L, Yu C, Fedoric B, Lopez AF, Galli SJ, Grimbaldeston MA: Evidence that vitamin D(3) promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice. J Exp Med 2010, 207(3):455-463.
- [51]Carmeliet P: Angiogenesis in health and disease. Nat Med 2003, 9(6):653-660.
PDF